Amgen, Inc. vs M&T Bank Corporation — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while M&T Bank Corporation trades at $251.93 (market cap $36.42B). The key difference: Amgen, Inc. is far larger — about 6.2× M&T Bank Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | MTB | |
|---|---|---|
Market Cap | $224.14B | $36.42B |
Sector | Health | Financials |
52-Week High | $417.20 | $254.04 |
52-Week Low | $271.18 | $178.63 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | 2.38% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →